The stock of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) has decreased by -1.75 when compared to last closing price of 4.57. Despite this, the company has experienced a -11.09% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf
Is It Worth Investing in Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Right Now?
The price-to-earnings ratio for Monte Rosa Therapeutics Inc (NASDAQ: GLUE) is above average at 66.82x, Company’s 36-month beta value is 1.41.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for GLUE is 45.99M, and currently, short sellers hold a 17.56% ratio of that floaft. The average trading volume of GLUE on June 19, 2025 was 662.69K shares.
GLUE’s Market Performance
The stock of Monte Rosa Therapeutics Inc (GLUE) has seen a -11.09% decrease in the past week, with a 9.25% rise in the past month, and a -32.99% fall in the past quarter. The volatility ratio for the week is 2.16%, and the volatility levels for the past 30 days are at 3.42% for GLUE. The simple moving average for the last 20 days is -0.92% for GLUE stock, with a simple moving average of -26.10% for the last 200 days.
Analysts’ Opinion of GLUE
Many brokerage firms have already submitted their reports for GLUE stocks, with Wells Fargo repeating the rating for GLUE by listing it as a “Equal Weight.” The predicted price for GLUE in the upcoming period, according to Wells Fargo is $11 based on the research report published on December 19, 2024 of the previous year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see GLUE reach a price target of $11. The rating they have provided for GLUE stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to GLUE, setting the target price at $18 in the report published on January 03rd of the previous year.
GLUE Trading at 0.57% from the 50-Day Moving Average
After a stumble in the market that brought GLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.79% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GLUE starting from Dunn Edmund, who sale 2,062 shares at the price of $4.45 back on Jun 03 ’25. After this action, Dunn Edmund now owns 23,732 shares of Monte Rosa Therapeutics Inc, valued at $9,174 using the latest closing price.
Leo Chandra P., the Director of Monte Rosa Therapeutics Inc, purchase 10,000 shares at $5.84 during a trade that took place back on Mar 24 ’25, which means that Leo Chandra P. is holding 10,000 shares at $58,383 based on the most recent closing price.
Stock Fundamentals for GLUE
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.97 for the gross margin
The net margin for Monte Rosa Therapeutics Inc stands at 0.04. The total capital return value is set at -0.01. Equity return is now at value 2.88, with 1.86 for asset returns.
Based on Monte Rosa Therapeutics Inc (GLUE), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at 0.83.
Currently, EBITDA for the company is -72.99 million with net debt to EBITDA at -5.97. When we switch over and look at the enterprise to sales, we see a ratio of 1.5. The receivables turnover for the company is 113.27for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.61.
Conclusion
In a nutshell, Monte Rosa Therapeutics Inc (GLUE) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
